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of immunosuppression (WHO criteria), use of antiretroviral 
therapy, CD4 counts, location of lesions, treatment used 
(surgery, chemotherapy, radiotherapy, combination), 
treatment duration, and estimates on survival. SPSS version 
20 was used in the statistical analysis. 
Results: A total of 63 cases fit the study criteria out of 113 
seen. Ratio of Epidemic vs. Endemic KS was 1: 1.8. Male to 
female ratio was 2.5: 1.The median age at presentation was 
48yrs (range 18-80yrs). The most frequent site was skin (90%) 
with 84% on the lower extremity and 6% disseminated. About 
60% of the HIV positive patients were on HAART. Median CD4 
count was 250cells/mm3 (range 1-549). Twenty four percent 
of the patients had both chemotherapy and radiotherapy, 
16% had chemotherapy only, 22% had radiotherapy only and 
38% refused treatment. The commonest chemotherapeutic 
agent used was Vincristine and others were Paclitaxel, 
Doxorubicin and Bleomycin. In all, 72% of the patients who 
received radiotherapy had good control with a minimum BED 
of 17.6Gy, out of which 52% had BED of 20Gy or less, 43% had 
BED between 20Gy and 40Gy and 5% greater than 40Gy. The 
most frequently prescribed radiation dose was 8Gy as a single 
dose. Other dose prescriptions used were 20Gy in 5 fractions 
and 30Gy in 10 fractions. The median follow period was 85 
days (range 1- 2241days). The overall survivals at 5years and 
10years were 41% and 6% respectively. 
Conclusions: The pattern of Kaposi’s sarcoma in Ghana 
differs from that of other Sub-Saharan African countries due 
to a relatively low rate of HIV infections, with endemic 
Kaposi sarcoma being almost twice as common. Radiotherapy 
is associated with good and durable local control to 
symptomatic sites. A BED at least 17.6Gy is required for local 
control of the disease. Follow up was however a limitation to 
this study. 
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Purpose/Objective: Breast sarcoma is a rare malignancy 
accounting for less than 1 percent of all breast malignancies 
and <5% of all soft tissue sarcomas It is a histologically 
heterogeneous non-epithelial malignancy arising from the 
breast connective tissue. Breast sarcoma can develop de novo 
or following radiation therapy. We present a case series 
analysis of all breast cancer sarcomas presented to our 
institution in a 14 year period. 
Materials and Methods: Data was retrospectively collected 
on all patients presenting with a histological diagnosis of 
breast sarcoma between 1999 and 2012. All cases have had 
histological confirmation of sarcoma diagnosis. Information 
collected on: age at diagnosis, presentation, tumour size, 
pathological and radiographic findings, treatment, breast 
cancer mortality and past medical history including prior 
radiotherapy. 
Results: Twenty-two patients were identified aged between 
15 and 84 (mean 54 years). Ten cases were in the right breast 
and ten within the left breast, one case was bilateral. 
Sixteen cases presented as a primary breast sarcoma, five 
presented as metastasis to the breast and skin overlying the 
breast, one presented as a metastasis from the breast. 
Tumour size was available for seventeen specimens ranging 
between 6mm and 130mm (mean 44.47mm). 
Histopathological diagnosis included sarcoma (not further 
specified) n=2, rhabdomyosarcoma n=3, myofibroblastic 
sarcoma n=2, leimyosarcoma n=1, angiosarcoma n=5, 
desmoids tumour with fibromatosis n=1, osteosarcoma n=1, 
liposarcoma n=1, spindle cell sarcomatosis n=1, stromal 
sarcoma n=2. 3 specimens revealed sarcomatoid features of 
uncertain origin. Surgical management included mastectomy 
(n=7), wide local excision (n=9), lumpectomy (n=3), one 
patient declined operative management and three patients 
lacked full clinical details.Ten patients presented with 
sarcoma in a previous radiotherapy field of which five of 
these were histologically angiosarcoma. Local recurrence was 
observed in two patients, two patients had distant metastatic 
disease. five patients presented with metastatic disease to 
the breast or the overlying skin, sixteen tumours presented 
primarily in the breast and one presented as metastasis to 
the tonsil.Ten of the twenty two patients died with a 
diagnosis of breast cancer. Tumour size > 5cm was not 
significantly associated with 5 year overall survival(p=0.63) in 
17 specimens for which tumour size was available. Influence 
of tumour grade on overall survival was not assessed due to 
insufficient clinical details. 
Conclusions: Our results indicate that prognosis in patients 
with breast sarcoma is still poor. Larger cohort of patients 
and more clinical research is required to improve treatment 
outcomes in patients with breast sarcomas. 
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Purpose/Objective: To assess the feasibility and local control 
of adjuvant radiotherapy in patients with BM after surgery. 
To analyze prognostic factors. 
Materials and Methods: 49 patients with resected BM from 
the lung, breast, gastrointestinal, genitourinary, and 
unknown origin were recruited (43 patients with 1 lesion and 
6 patients with 2 lesions). Ten patients were RPA class I, 38 
patients class II, and 1 patient class III. The GPA score was 
0.5 in 1 patient, 1.5 in 15 patients, 2.0 in 8 patients, 2.5 in 5 
patients, 3.0 in 12 patients, 3.5 in 6 patients, and 4.0 in 2 
patients. 24 out of 49 patients had synchronous BM. 
Results: A total of 11 patients received a single treatment 
session, 27 patients received hypofractionated stereotactic 
radiation regimen, while 11 cases were treated with focal 3D 
radiation with/without cone beam. After a median follow-up 
of 15.2 months, the median disease-free progression time 
was 11.3 months (95% CI, 6.4-16.3). The actuarial local 
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control at 12m was 48.4%. The median survival time was 30.9 
m for all patients. Delayed whole brain radiotherapy was 
needed in 13 patients. Applying univariate analysis no 
differences were observed either in BM volume, type of 
primary tumor, radiation doses, RPA and GPA indexes or time 
of presentation (synchronous vs. metachronous BM). One case 
of confirmed radiation necrosis was observed. 
Conclusions: Adjuvant RT after BM excision is safe, feasible 
and might avoid whole brain radiotherapy in a significant 
percentage of patients. We have not found differences 
between synchronous vs. metachronous presentation. 
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Purpose/Objective: Whole Lung Irradiation (WLI) is an option 
for pediatric Ewing Sarcoma (ES) with pulmonary metastases 
(PM) at time of diagnosis. At our institution, patients with 
Ewing's Sarcoma (ES) and PM at time of diagnosis are treated 
with WLI. The aim of this study was to analyze feasibility, 
overall survival and disease free survival in a homogeneous 
population.  
Materials and Methods: Seventeen patients were included in 
this retrospective, monocentric study. All patients underwent 
a local therapy on the site of primary tumor (surgery and/or 
radiation therapy) and a systemic treatment with induction 
chemotherapy (Vincristin, Adriamicin, Ifosfamide and 
Etoposide). Patients whose pulmonary metastases not 
responded at induction chemotherapy were 5 (29.4%), and 
underwent surgical resection of PM. All patients underwent 
systemic consolidation treatment with HDCT (Busulfan plus 
Melphalan) followed by WLI, that was administered by three 
dimensional (3D) conformal radiation therapy at dose of 15 
Gy in 10 fractions (fr) (in patients > 12 years old) or 12 Gy in 
10/fr (in pediatric patients). Patients demographics, fields of 
irradiation, local treatment and systemic treatment were 
collected. All patients were evaluated by clinical and 
radiological exams during the follow up. Duration of survival 
was defined as the time interval between diagnosis and death 
from any cause or most recent follow-up visit. Duration of 
disease free survival was defined as the time interval 
between diagnosis and disease recurrence or progression, 
death or most recent follow-up visit. 
Results: Mean age at time of diagnosis was 16.1 years (range 
7-34). The mean follow up time of surviving patients was 34.9 
months (range 10-84). The rate of pulmonary relapse (PR) 
was 52%. At 12, 24 and 36 months, DFS was 80.7%, 53.8% and 
40.3% and OS was 100%, 78% and 54.5%. Younger patients (< 
16 years old) had a higher survival (at 12, 24 and 36 months: 
100%, 100%, 85% vs 100%, 53.6 and 17.9%, respectively; 
p=0.005; Figure). Radiation pneumonitis developed in three 
patients at a median of 3 month (2,3,4 months) after WLI and 
was successfully treated with steroids. No clinically evident 
deterioration in pulmonary function was detected.  
 
Conclusions: Bilateral whole lung irradiation is a simple 
procedure with few acute or late sequelae. Our finding 
showed that pediatric patients had a higher survival. Further 
trials are necessary to define the WLI role in adults. 
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Purpose/Objective: Studies in advanced Hodgkin lymphoma 
(HL) suggest many relapses occur at the sites of initial 
disease, and have been used to justify the use of 
consolidative radiotherapy (RT). However, the chemotherapy 
regimens used in these studies vary from current practice and 
positron emission tomography (PET) was not used for 
assessment of stage or response. The aim of this study is to 
characterise patterns of relapse and survival outcomes in 
patients with PET staged advanced HL treated with the 
chemotherapy regimen of doxorubicin, bleomycin, vinblastine 
and dacarbazine (ABVD). 
Materials and Methods: Patients over 18 years old with 
newly diagnosed Stage III or IV HL treated with ABVD 
chemotherapy at our institution from January 2005 to 
December 2012 were included in this study. All patients were 
evaluated with PET prior to chemotherapy for staging and 
following chemotherapy to assess response. Patients were 
given consolidative RT at the discretion of treating clinicians. 
Patterns of relapse, disease-free survival (DFS) (measured 
from attainment of a complete response (CR) to disease 
recurrence or death), progression-free survival (PFS) 
(measured from first day of chemotherapy to lymphoma 
progression or death) and overall survival (OS) (measured 
